To include your compound in the COVID-19 Resource Center, submit it here.

A two-way street in metabolic disease

A two-way flow of information between lab and clinic has enabled research collaborators at the Sanford-Burnham Medical Research Institute and The Translational Research Institute for Metabolism and Diabetes to identify markers that reflect subsets of heterogeneous metabolic diseases better than current markers.

The institutes have partnered with Takeda Pharmaceutical Co. Ltd. to support the pharma's obesity programs and will expand their resources as they forge additional alliances.

The Translational Research Institute (TRI) conducts clinical studies while a team at Sanford-Burnham's Lake Nona campus in Orlando, Fla., conducts preclinical research and provides metabolomics analyses.

TRI itself is a 2009 joint

Read the full 966 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE